SEC For	m 4															
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL				
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).				Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								HIP	Estima	Number: ated average bui per response:	3235-0287 den 0.5	
1. Name and Address of Reporting Person* Lamb Peter					2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>EXELIXIS</u> , <u>INC</u> . [EXEL]						(Che	eck all applic Directo	able)	, 10% Own		
(Last) (First) (Middle) C/O EXELIXIS, INC. 1851 HARBOR BAY PARKWAY					3. Date of Earliest Transaction (Month/Day/Year) 10/15/2021							below)	Gcientific Strategy & CSO		v)	
					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) ALAMEDA CA 94502												X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)																
		Ta	ble I - No	on-Deriv	ative S	Securities Ac	quired	l, Dis	posed of	, or Bei	neficiall	y Owned				
				2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			Benefici Owned F	s F ally (I ollowing (I	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
							Code	v	Amount	(A) or (D)	Price	Reported Transact (Instr. 3	ion(s)		(Instr. 4)	
Common Stock				10/15/2021			М		47,500	A	\$6.21	458,740(1)		D		
Common Stock				10/15/2021			S <sup>(2)</sup>		47,500 D		\$21.92	3) 411,240		D		
Common Stock												17,105(4)		I	By 401(k)	
			Table II			ecurities Acq alls, warrants						Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date, T	ransactio ode (Inst		6. Date E Expiratic (Month/E	on Date	•	7. Title an of Securit Underlyin Derivative (Instr. 3 a	g Security	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transactie (Instr. 4)	e Owners 5 Form: Ily Direct (I or Indire (I) (Instr	Beneficial Ownership ect (Instr. 4)	

2. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2021.

Explanation of Responses:

\$6.21

3. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$21.69 to \$22.07. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

Date Exercisable

09/16/2016<sup>(5)</sup>

Expiration Date

09/15/2022

Title

Common

Stock

4. Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of October 14, 2021.

5. The option, representing the right to purchase a total of 190,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 16, 2019.

v

Code

Μ

1. Includes 229,577 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

(A) (D)

47,500

**Remarks:** 

Option

(right to buy)

## /s/ Jennifer Drimmer Rokovich, Atterners in Fost

Attorney in Fact

\*\* Signature of Reporting Person Date

Amount or Number

of Shares

47,500

\$<mark>0</mark>

95,000

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

10/15/2021

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.